Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California

BACKGROUND: Bedaquiline (BDQ) is recommended for the treatment of multidrug-resistant tuberculosis (MDR TB), however, it has the potential to prolong QTc interval. We assessed the frequency and severity of QTc prolongation in patients receiving BDQ in California. METHODS: Based on chart review for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Katrak, Shereen, Lowenthal, Phil, Shen, Richard, True, Lisa, Henry, Leslie, Barry, Pennan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868725/
https://www.ncbi.nlm.nih.gov/pubmed/33598568
http://dx.doi.org/10.1016/j.jctube.2021.100216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868725/
https://www.ncbi.nlm.nih.gov/pubmed/33598568
http://dx.doi.org/10.1016/j.jctube.2021.100216

Ejemplares similares